Actively Recruiting
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Led by The First Affiliated Hospital of Soochow University · Updated on 2024-05-01
60
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.
CONDITIONS
Official Title
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL).
- Age 18-65.
- ECOG score between 0 and 2.
- No prior chemotherapy or targeted therapy.
- Serum total bilirubin less than or equal to 2 times the upper limit of normal (ULN).
- Alanine aminotransferase (ALT) less than or equal to 1.5 times ULN.
- Aspartate aminotransferase (AST) less than or equal to 1.5 times ULN.
- Creatinine clearance rate of at least 30 mL/min.
- Serum lipase less than or equal to 1.5 times ULN.
- Serum amylase less than or equal to 1.5 times ULN.
- Able to understand and willing to participate in the study and have signed the informed consent form.
You will not qualify if you...
- AML transformed from chronic myelogenous leukemia.
- Acute promyelocytic leukemia (type M3).
- Having a second malignancy that requires treatment.
- Uncontrolled active infection.
- Left ventricular ejection fraction less than 0.5 or grade III/IV cardiovascular dysfunction.
- Hepatic and renal inadequacy: total serum bilirubin 2.0 mg/dl or higher, AST 3 times ULN or higher, creatinine clearance less than 50 ml/min.
- Arterial oxygen saturation below 95%.
- HIV infection.
- Active hepatitis B or hepatitis C infection.
- Other medical conditions deemed unsuitable by investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
X
Xiaowen Tang, Ph.D
CONTACT
D
Depei Wu, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here